Prostate Cancer Therapeutics Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis
市場洞察とアナリストの見解:
前立腺がん治療薬の市場規模は、新薬化合物導入のための研究開発活動の活発化により拡大しており、前立腺がん治療薬の数は増加しています。がんの症例、および前立腺がんの診断に対する政府の支援の増加。さらに、市場参加者が先進的な製品を入手できることが市場の成長を促進します。 2023年1月、BDRファーマシューティカルはインドで前立腺がんの治療に使用されるアパルタミドのジェネリック版を発売した。この薬はAPATIDEというブランドで発売され、非転移性去勢抵抗性前立腺がんおよび転移性去勢感受性前立腺がんの治療に処方されています。
成長の原動力と課題:
前立腺がんは最も一般的な健康問題の1つです。男性、特に50歳以上の高齢男性に多くみられます。前立腺がんは、肥満で前立腺がんの家族歴がある男性によく見られます。前立腺がんは目立った症状なしに発症することが多いため、静かな脅威です。したがって、このがんの早期発見はそれほど簡単ではありません。前立腺がんの大部分は、前立腺の周辺領域で発生します。症状が明らかになるには、がんが尿道を圧迫する大きさに達する必要があります。そうでない場合、転移による骨の痛みが進行前立腺がんの最初の症状となる場合があります。ただし、50 歳以上で下部尿路症状、勃起不全、血尿がある場合は、前立腺がんの可能性を考慮する必要があります。前立腺がんは、世界中の男性のがんによる死亡原因の第 5 位であり、2 番目に多く診断されるがんです。 2000 年以降、前立腺がんの発生率は減少していますが、2010 年からは後期前立腺がんの発生率が増加しています。前立腺がんの発生率と死亡率は大きく異なります。先進国では一般に前立腺がんの発生率が高いが、死亡率は低い。米国の前立腺がんのリスクは、世界のリスクのほぼ 4 倍です。 Novartis AG によると、2020 年には世界中で約 140 万人の新たな前立腺がん症例と約 375,000 人の前立腺がんによる死亡が報告されました。世界中で前立腺がんの症例数が増加していることと、前立腺がんの検出率が低いことが、前立腺がん治療薬市場の成長を促進しています。
レポートの細分化と範囲:
前立腺がん治療薬市場は、治療法に基づいて分類されています。タイプ、エンドユーザー、および地理。前立腺がん治療薬市場は、治療の種類ごとに、ホルモン療法、化学療法、免疫療法、標的療法などに分類されます。前立腺がん治療薬市場は、エンドユーザーごとに病院、専門クリニックなどに分割されています。前立腺がん治療薬市場は地理に基づいて、北米(米国、カナダ、メキシコ)、欧州(英国、ドイツ、フランス、イタリア、スペイン、その他の欧州)、アジア太平洋(中国、日本)に分割されています。 、インド、韓国、オーストラリア、その他のアジア太平洋地域)、中東およびアフリカ(UAE、サウジアラビア、南アフリカ、およびその他の中東およびアフリカ)、中南米(ブラジル、アルゼンチン)
セグメント分析:
前立腺がん治療薬市場は、治療の種類ごとに、ホルモン療法、化学療法、免疫療法、標的療法などに分割されています。 2022 年には、ホルモン療法セグメントが化学療法に次いで最大の市場シェアを保持し、同セグメントは 2022 年から 2030 年にかけて最高の CAGR を記録すると予想されています。化学療法は前立腺がんの重要な治療法と考えられています。この療法では、薬剤が肺内の新規または既存の癌細胞を破壊します。転移性前立腺がんに対する化学療法は症状を軽減することができます。また、がんを軽減し、生活の質を向上させるのにも役立ちます。ドセタキセル(タキソテール)は、ホルモン療法に抵抗性のある患者の前立腺がん化学療法における標準治療と考えられています。 FDAはまた、去勢抵抗性前立腺がんの治療に化学療法薬カバジタキセル(Jevtana)を承認した。ドセタキセル服用中に増殖した転移性前立腺がんの患者にも使用されます。
前立腺がん治療薬市場、エンドユーザー別 - 2022年および2030年
地域分析:
前立腺がん治療薬市場は地理的に分割されています。北米、ヨーロッパ、アジア太平洋、中東とアフリカ、南米と中央アメリカに展開します。北米は世界の前立腺がん治療薬市場の成長に最大の貢献国です。アジア太平洋地域は、2022年から2030年にかけて前立腺がん治療薬市場で最高のCAGRを記録すると予想されています。米国の前立腺がん治療薬市場の成長は、主に前立腺がん症例の増加、製品の発売、政府の取り組みによって推進されています。 2023年6月、アストラゼネカとMSDのリムパーザ(オラパリブ)とプレドニゾンまたはプレドニゾロンとアビラテロンの併用が、有害なBRCA変異(BRCAm)が疑われる転移性去勢抵抗性前立腺がん(mCRPC)の成人患者の治療薬として米国で承認された。さらに、2023 年 11 月には、FDA がアステラス製薬 US, Inc. が製造するエンザルタミドを承認しました。この製品は、転移リスクが高く生化学的再発を伴う非転移性去勢感受性前立腺がん(nmCSPC)(高リスクBCR)の治療に使用されます。
業界の発展と将来の機会:
キーごとのさまざまな取り組み前立腺がん治療薬市場で活動するプレーヤーは以下のとおりです。
2022年3月、米国FDAは、前立腺特異的膜抗原と呼ばれる一種の進行性前立腺がんの成人患者の治療にノバルティスのPluvicto(ルテチウムLu 177ビピボチドテトラキセタン)を承認しました。転移性去勢抵抗性前立腺がん陽性(PSMA陽性mCRPC)。 2023年4月、FDAはランテウス・ホールディングス社とポイント・バイオファーマ・グローバル社に対し、転移性去勢抵抗性前立腺がん(mCRPC)の治療薬として177Lu-PNT2002のファストトラック指定を付与した。 PNT2002 は、mCRPC を治療するために、PSMA 標的リガンド、PSMA-I&T、およびキャリア無添加のベータ線放射性同位体 177Lu を組み合わせた、革新的な PSMA 標的 177Lu ベースの放射性医薬品治療です。競争環境と主要企業:
アステラス製薬株式会社、Johnson & Johnson Services Inc、Eli Lilly and Company、Bayer AG、Sanofi、Merck KGaA、AstraZeneca、Novartis AG、AbbVie、および Bristol Myers Squibb は、前立腺がん治療薬市場で活動する著名なプレーヤーの 1 つです。これらの市場関係者は、世界中で高まる消費者の需要に応え、専門ポートフォリオの製品範囲を拡大するために、新製品の発売と地理的拡大に重点を置いています。同社の世界的なプレゼンスにより、大規模な顧客基盤にサービスを提供できるようになり、その後の市場拡大が促進されます。
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Based on geography, the prostate cancer therapeutics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to global prostate cancer therapeutics market growth. Asia Pacific is expected to register the highest CAGR in the prostate cancer therapeutics market from 2022 to 2030.
The prostate cancer therapeutics market, by therapy type, is segmented into hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. In 2022, the chemotherapy segment held the largest market share, and the same segment is expected to record the highest CAGR from 2022 to 2030.
The prostate cancer therapeutics market, by end-user, is segmented into hospitals, specialty clinics, and others. In 2022, the hospital segment held the largest market share; moreover, the same segment is expected to record the highest CAGR during 2022–2030.
The increasing cases of prostate cancer and strategic initiatives in prostate cancer therapeutics freezer bolster the prostate cancer therapeutics market size. However, the high cost associated with prostate cancer therapeutics hinders the growth of prostate cancer therapeutics market growth.
The prostate cancer therapeutics market majorly consists of players such Astella Pharma Inc, Johnson & Johnson Services Inc, Eli Lilly and Company, Bayer AG, Sanofi, Merck KGaA, AstraZeneca, Novartis AG, AbbVie, and Bristol Myers Squibb
Prostate cancer is one of the most common health problems in men, especially in older men (aged above 50 years). Prostate cancer is mostly common in men who are obese and have a family history of prostate cancer. Prostate cancer is a silent threat that often develops without noticeable symptoms, and hence, early detection of this cancer is not that easy. Typically, the majority of prostate cancers originate in the peripheral region of the prostate gland. Consequently, for symptoms to become apparent, the cancer must reach a size where it exerts pressure on the urethra, or in some cases, bone pain from the metastasis might be the initial presenting symptom of advanced prostate cancer. However, any individual aged 50 or above who presents with lower urinary tract symptoms, erectile dysfunction, or hematuria should consider the possibility of prostate cancer.
The List of Companies - Prostate Cancer Market
- Astella Pharma Inc
- Johnson & Johnson Services Inc
- Eli Lilly, and Company
- Bayer AG
- Sanofi
- Merck KGaA
- AstraZeneca
- Novartis AG
- AbbVie
- Bristol Myers Squibb
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.